Financière de Tubize SA (TUB.BR)
EUR 138.8
(-0.86%)
EUR 138.8
(-0.86%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 1.92 Billion EUR | 4.43% |
| 2022 | 1.83 Billion EUR | -43.73% |
| 2021 | 3.26 Billion EUR | 15.58% |
| 2020 | 2.82 Billion EUR | 2.74% |
| 2019 | 2.75 Billion EUR | 10.8% |
| 2018 | 2.48 Billion EUR | 7.45% |
| 2017 | 2.31 Billion EUR | 3.98% |
| 2016 | 2.22 Billion EUR | -1.61% |
| 2015 | 2.25 Billion EUR | 23.09% |
| 2014 | 1.83 Billion EUR | 1.7% |
| 2013 | 1.8 Billion EUR | 1.05% |
| 2012 | 1.78 Billion EUR | -4.42% |
| 2011 | 1.86 Billion EUR | 4.69% |
| 2010 | 1.78 Billion EUR | 3.55% |
| 2009 | 1.72 Billion EUR | 8.73% |
| 2008 | 1.58 Billion EUR | -5.36% |
| 2007 | 1.67 Billion EUR | 4.99% |
| 2006 | 1.59 Billion EUR | 56.57% |
| 2005 | 1.01 Billion EUR | 42.46% |
| 2004 | 715.25 Million EUR | -9.58% |
| 2003 | 791.02 Million EUR | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 1.92 Billion EUR | 0.0% |
| 2023 FY | 1.92 Billion EUR | 4.43% |
| 2023 Q2 | 1.89 Billion EUR | 0.0% |
| 2023 Q4 | 1.92 Billion EUR | 0.0% |
| 2022 Q2 | 3.52 Billion EUR | 0.0% |
| 2022 FY | 1.83 Billion EUR | -43.73% |
| 2022 Q4 | 1.83 Billion EUR | 0.0% |
| 2021 FY | 3.26 Billion EUR | 15.58% |
| 2021 Q4 | 3.26 Billion EUR | 0.0% |
| 2021 Q2 | 2.99 Billion EUR | 0.0% |
| 2020 FY | 2.82 Billion EUR | 2.74% |
| 2020 Q4 | 2.82 Billion EUR | 0.0% |
| 2020 Q2 | 2.76 Billion EUR | 0.0% |
| 2019 Q2 | 2.55 Billion EUR | 0.0% |
| 2019 Q4 | 2.75 Billion EUR | 0.0% |
| 2019 FY | 2.75 Billion EUR | 10.8% |
| 2018 Q4 | 2.48 Billion EUR | 0.0% |
| 2018 FY | 2.48 Billion EUR | 7.45% |
| 2018 Q2 | 2.37 Billion EUR | 0.0% |
| 2017 Q2 | 2.23 Billion EUR | 0.0% |
| 2017 FY | 2.31 Billion EUR | 3.98% |
| 2017 Q4 | 2.31 Billion EUR | 0.0% |
| 2016 FY | 2.22 Billion EUR | -1.61% |
| 2016 Q2 | 2.08 Billion EUR | 0.0% |
| 2016 Q4 | 2.22 Billion EUR | 0.0% |
| 2015 FY | 2.25 Billion EUR | 23.09% |
| 2015 Q2 | 1.94 Billion EUR | 0.0% |
| 2015 Q4 | 2.25 Billion EUR | 0.0% |
| 2014 Q4 | 1.83 Billion EUR | 0.0% |
| 2014 Q2 | 1.79 Billion EUR | 0.0% |
| 2014 FY | 1.83 Billion EUR | 1.7% |
| 2013 FY | 1.8 Billion EUR | 1.05% |
| 2013 Q4 | 1.8 Billion EUR | 0.0% |
| 2013 Q2 | 1.77 Billion EUR | 0.0% |
| 2012 Q4 | 1.78 Billion EUR | 0.0% |
| 2012 Q2 | 1.86 Billion EUR | 0.0% |
| 2012 FY | 1.78 Billion EUR | -4.42% |
| 2011 Q2 | 1.84 Billion EUR | 0.0% |
| 2011 FY | 1.86 Billion EUR | 4.69% |
| 2011 Q4 | 1.86 Billion EUR | 0.0% |
| 2010 Q2 | 1.82 Billion EUR | 0.0% |
| 2010 FY | 1.78 Billion EUR | 3.55% |
| 2010 Q4 | 1.78 Billion EUR | 0.0% |
| 2009 Q4 | 1.72 Billion EUR | 0.0% |
| 2009 FY | 1.72 Billion EUR | 8.73% |
| 2008 FY | 1.58 Billion EUR | -5.36% |
| 2007 FY | 1.67 Billion EUR | 4.99% |
| 2006 FY | 1.59 Billion EUR | 56.57% |
| 2005 FY | 1.01 Billion EUR | 42.46% |
| 2004 FY | 715.25 Million EUR | -9.58% |
| 2003 FY | 791.02 Million EUR | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| ABIONYX Pharma SA | 14.71 Million EUR | -12954.007% |
| ABIVAX Société Anonyme | 327.06 Million EUR | -487.119% |
| Adocia SA | 24.95 Million EUR | -7594.52% |
| Aelis Farma SA | 26.28 Million EUR | -7206.588% |
| Biophytis S.A. | 11.93 Million EUR | -15987.839% |
| Advicenne S.A. | 12.4 Million EUR | -15377.105% |
| genOway Société anonyme | 31.84 Million EUR | -5930.47% |
| IntegraGen SA | 8 Million EUR | -23902.003% |
| Medesis Pharma S.A. | 1.92 Million EUR | -99583.827% |
| Neovacs S.A. | 47.53 Million EUR | -3939.763% |
| NFL Biosciences SA | 3.97 Million EUR | -48261.228% |
| Plant Advanced Technologies SA | 14.91 Million EUR | -12776.377% |
| Quantum Genomics Société Anonyme | 3.74 Million EUR | -51150.649% |
| Sensorion SA | 46.49 Million EUR | -4030.084% |
| Theranexus Société Anonyme | 7.23 Million EUR | -26431.006% |
| TME Pharma N.V. | 2.49 Million EUR | -76987.292% |
| Valbiotis SA | 33.24 Million EUR | -5675.519% |
| TheraVet SA | 7.53 Million EUR | -25387.072% |
| Valerio Therapeutics Société anonyme | 35.27 Million EUR | -5343.796% |
| argenx SE | 4.11 Billion EUR | 53.303% |
| BioSenic S.A. | 9.55 Million EUR | -19988.34% |
| Celyad Oncology SA | 16.28 Million EUR | -11693.664% |
| DBV Technologies S.A. | 165.65 Million USD | -1059.213% |
| Galapagos NV | 4.35 Billion EUR | 55.931% |
| Genfit S.A. | 173.87 Million EUR | -1004.401% |
| GeNeuro SA | 6.31 Million EUR | -30317.787% |
| Hyloris Pharmaceuticals SA | 47.68 Million EUR | -3927.274% |
| Innate Pharma S.A. | 184.19 Million EUR | -942.518% |
| Inventiva S.A. | 69.13 Million EUR | -2677.368% |
| MaaT Pharma SA | 42.93 Million EUR | -4372.862% |
| MedinCell S.A. | 36.94 Million EUR | -5097.154% |
| Nanobiotix S.A. | 93.89 Million EUR | -1945.054% |
| Onward Medical N.V. | 43.62 Million EUR | -4301.303% |
| Oryzon Genomics S.A. | 106.9 Million EUR | -1696.298% |
| OSE Immunotherapeutics SA | 81.9 Million EUR | -2244.621% |
| Oxurion NV | 6.55 Million EUR | -29216.709% |
| Pharming Group N.V. | 426.33 Million EUR | -350.403% |
| Poxel S.A. | 4.82 Million EUR | -39714.316% |
| GenSight Biologics S.A. | 9.08 Million EUR | -21031.776% |
| Transgene SA | 45.21 Million EUR | -4146.731% |
| UCB SA | 15.53 Billion EUR | 87.642% |
| Valneva SE | 469.39 Million EUR | -309.093% |
| Vivoryon Therapeutics N.V. | 30.82 Million EUR | -6128.695% |